BioSpace News Archive

Anaveon announced the first patient dosed with ANV419 in the OMNIA-2 study - a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.

OKYO Pharma Limited announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website.

MediWound Ltd. is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023.

Invivyd, Inc. today announced that it will host a conference call on Thursday, March 23, 2023, at 4:30 p.m. ET to discuss its financial results for the full year ended December 31, 2022, and recent business highlights.

Augmedix Inc. today announced it will report financial results for the fourth quarter and full-year ended December 31, 2022 on Monday, March 27, 2023, before the market opens.

Cabaletta Bio, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.

BioCardia ® , Inc. today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET.

Evelo Biosciences, Inc. today reported financial results and business highlights for the fourth quarter and full year 2022.

UCB, a global biopharmaceutical company, today announced that it will present eight bimekizumab abstracts across a range of IL-17 mediated diseases.